title: Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
abstract: BACKGROUND
  The recombinant humanized anti-IgE antibody omalizumab rapidly reduces serum free IgE concentrations and alleviates allergic airway disease. It is not known whether stopping or reducing the dose of omalizumab maintains adequate suppression of free IgE levels and IgE-mediated mast cell activation.
  
  
  OBJECTIVE
  To determine the effects of omalizumab on serum free IgE and immediate allergen skin test reactivity during initial therapy followed by treatment reduction and cessation.
  
  
  METHODS
  Forty patients with perennial allergic rhinitis were randomized to receive 0.015 or 0.030 mg/kg/IU/mL open-label intravenous omalizumab every 2 weeks for 28 weeks, followed by 0.0015 or 0.0050 mg/kg/IU/mL every 2 weeks for 18 weeks. Serum free IgE levels were measured and titrated dust mite allergen skin tests conducted throughout.
  
  
  RESULTS
  At day 98, serum free IgE concentrations were decreased by 96% to 99%, and wheal-and-flare reactions to skin tests were markedly suppressed. After reduced omalizumab doses (day 322), serum free IgE and allergen skin test reactivity increased significantly. On complete discontinuation of therapy (day 378), serum free IgE levels and skin test reactivity returned to baseline levels. Patients with lower initial levels of IgE had significantly less suppression of skin test reactivity.
  
  
  CONCLUSIONS
  Omalizumab reduced serum free IgE and immediate skin test reactivity to allergen during initial, high-dose administration. These effects were not fully maintained during dose reduction and returned to baseline after cessation of chronic treatment.
authors.affiliation: Allergy Research Foundation, Los Angeles, CA 90025, USA. jcorren@ucla.edu
authors.forename: Jonathan
authors.initials: J
authors.lastname: Corren
authors.forename: Gail
authors.initials: G
authors.lastname: Shapiro
authors.forename: James
authors.initials: J
authors.lastname: Reimann
authors.forename: Yamo
authors.initials: Y
authors.lastname: Deniz
authors.forename: Dennis
authors.initials: D
authors.lastname: Wong
authors.forename: Daniel
authors.initials: D
authors.lastname: Adelman
authors.forename: Alkis
authors.initials: A
authors.lastname: Togias
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D039741:Antigens, Dermatophagoides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D007275:Injections, Intravenous; D008297:Male; D000069444:Omalizumab; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D012882:Skin Tests
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039741:Antigens, Dermatophagoides; D000069444:Omalizumab; D007073:Immunoglobulin E